Drug intelligence / Profile preview

PTH-0317

Development stage: Unknown
Lead developer: Protheragen
Modality: Small Molecules
Administration: Oral

Overview

PTH-0317 is a small molecule inhibitor of RAS proteins developed by Protheragen for the treatment of solid tumors. RAS proteins (KRAS, HRAS, and NRAS) are small GTPases that act as critical nodes in signaling pathways controlling cell growth, differentiation, and survival. Mutations in RAS genes are highly prevalent in various cancers, leading to constitutive activation and uncontrolled tumor growth. PTH-0317 is designed to target these proteins and is currently in Phase 1 clinical development.

Targets

PPIA (Peptidyl-prolyl cis-trans isomerase A)HRAS (H-Ras protein)NRAS (Neuroblastoma RAS viral oncogene homolog)KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on PTH-0317.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTH-0317.

Explore the full profile